1. Home
  2. QD vs MNMD Comparison

QD vs MNMD Comparison

Compare QD & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QD
  • MNMD
  • Stock Information
  • Founded
  • QD 2014
  • MNMD 2019
  • Country
  • QD China
  • MNMD United States
  • Employees
  • QD N/A
  • MNMD N/A
  • Industry
  • QD Finance: Consumer Services
  • MNMD Pharmaceuticals and Biotechnology
  • Sector
  • QD Finance
  • MNMD Health Care
  • Exchange
  • QD Nasdaq
  • MNMD Nasdaq
  • Market Cap
  • QD 754.6M
  • MNMD 709.9M
  • IPO Year
  • QD 2017
  • MNMD N/A
  • Fundamental
  • Price
  • QD $4.12
  • MNMD $9.57
  • Analyst Decision
  • QD
  • MNMD Strong Buy
  • Analyst Count
  • QD 0
  • MNMD 7
  • Target Price
  • QD N/A
  • MNMD $24.71
  • AVG Volume (30 Days)
  • QD 392.3K
  • MNMD 1.1M
  • Earning Date
  • QD 08-13-2025
  • MNMD 11-06-2025
  • Dividend Yield
  • QD N/A
  • MNMD N/A
  • EPS Growth
  • QD N/A
  • MNMD N/A
  • EPS
  • QD 0.42
  • MNMD N/A
  • Revenue
  • QD $19,058,373.00
  • MNMD N/A
  • Revenue This Year
  • QD N/A
  • MNMD N/A
  • Revenue Next Year
  • QD N/A
  • MNMD N/A
  • P/E Ratio
  • QD $9.83
  • MNMD N/A
  • Revenue Growth
  • QD N/A
  • MNMD N/A
  • 52 Week Low
  • QD $1.77
  • MNMD $4.70
  • 52 Week High
  • QD $5.08
  • MNMD $11.02
  • Technical
  • Relative Strength Index (RSI)
  • QD 44.40
  • MNMD 51.80
  • Support Level
  • QD $4.08
  • MNMD $8.70
  • Resistance Level
  • QD $4.37
  • MNMD $9.95
  • Average True Range (ATR)
  • QD 0.17
  • MNMD 0.52
  • MACD
  • QD -0.08
  • MNMD -0.01
  • Stochastic Oscillator
  • QD 5.22
  • MNMD 54.37

About QD Qudian Inc. each representing one

Qudian Inc is a consumer-oriented technology company engaged in the operation of online platforms to provide small consumer credit products in the People's Republic of China. It aims to empower financial institutions with its technological capabilities, help them improve marketing and operating efficiency, and enable financial institutions to efficiently connect their diversified financial products with scene traffic across the entire network It derives a majority of its revenue from the People's Republic of China.

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Share on Social Networks: